Debate: Single-fraction treatment should be standard in the retreatment of uncomplicated bone metastases

Derek S. Tsang, Vivian Yau, Hamid Raziee, Mark Niglas, Hany Soliman, Edward Chow, May Tsao

Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada

Correspondence to: Dr. May Tsao, MD, FRCPC. Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada. Email: may.tsao@sunnybrook.ca.

Abstract: There is controversy surrounding the optimal radiotherapy dose-fractionation for retreatment of painful bone metastases. Two commonly used regimens are 8 Gy in a single-fraction or 20 Gy in five or eight fractions. Randomized evidence, including the NCIC SC.20 randomized clinical trial, has failed to standardize clinical practice. Practitioners who use single-fraction regimens cite patient convenience, fewer acute adverse effects, and better cost-effectiveness. Practitioners who prefer multiple fractions raise questions about the interpretation of data that justifies single-fraction treatment, and the possibility that single-fraction treatment may provide inferior pain relief. Given this clinical controversy, should single-fraction irradiation be standard in retreatment of uncomplicated bone metastases? In this article, two teams debate both sides of the argument with commentary to summarize the relevant issues. The conclusion from the debate is that the “standard” treatment should be individualized to the patient with shared-decision making between the oncologist, patient and family members. In a cancer patient with poor performance status and short life expectancy, single-fraction repeat radiotherapy may be preferred; in a patient with a prolonged disease course, perhaps multiple fraction retreatments would be preferred. The choice between different fractionation schemes depends on an assessment of individual patient factors, tumour factors and unique patient circumstances.

Keywords: Bone and bones; metastases; neoplasm; pain; palliative care; radiotherapy; retreatment

Submitted Jul 15, 2015. Accepted for publication Aug 21, 2015.
doi: 10.3978/j.issn.2224-5820.2015.08.05
View this article at: http://dx.doi.org/10.3978/j.issn.2224-5820.2015.08.05

Editor's note:
“Palliative Radiotherapy Column” features articles emphasizing the critical role of radiotherapy in palliative care. Chairs to the columns are Dr. Edward L.W. Chow from Odette Cancer Centre, Sunnybrook Health Sciences Centre in Toronto and Dr. Stephen Lutz from Blanchard Valley Regional Cancer Center in Findlay, gathering a group of promising researchers in the field to make it an excellent column. The column includes original research manuscripts and timely review articles and perspectives relating to palliative radiotherapy, as well as editorials and commentaries on recently published trials and studies.
treatment be standard in the retreatment of uncomplicated bone metastases? We emphatically believe so. Evidence in support of this will be reviewed, and how this information can be applied to day-to-day practice in palliative radiation oncology will be discussed.

There are two RCTs examining retreatment of painful bone metastases. The first trial, although small, deserves mention. In a single-institution, prospective RCT, Sayed et al. randomized 60 patients to 8 Gy single-fraction retreatment or 20 Gy in multiple fractions (five to eight, depending on site) (7). Although the study was underpowered to detect small differences and an a priori sample size calculation was not reported, the authors found no statistically significant difference in pain response between the two treatment groups.

The second trial, coordinated by the NCIC Clinical Trials Group (CTG), provides the bulk of the high-quality evidence available to answer our question. Also termed the SC.20 trial, Chow et al. randomized 850 patients to receive 8 Gy single-fraction retreatment or 20 Gy in multiple fractions (8). The trial was designed as a non-inferiority study with a pre-specified non-inferiority margin of 10%. The primary analysis was based on the intention-to-treat population, which found that overall response rate was inferior in the single-fraction arm by 4% (absolute difference) as compared with multiple-fractions (P=0.21, not statistically significant). The upper 95% confidence interval (CI) was 9.2%, thus excluding the possibility that single-fraction treatment was 10% worse. A per-protocol sensitivity analysis was performed, which demonstrated a 6% absolute decrease in response rate and an upper 95% CI of 13.2%, suggesting a possibility that single-fraction treatment could have up to 13.2% reduced pain response.

A brief discussion about clinical trial interpretation and analysis is in order. In superiority clinical trials, intention-to-treat analysis is considered a gold standard of data analysis, as it reduces the chance of a type I error (9-11). In non-inferiority trials, it has traditionally been favoured to use a per-protocol analysis as this reduces the chance that an inferior treatment appears equally efficacious to the comparator treatment due to methodological issues such as treatment non-adherence or missing data (10-12). Missing data negatively affects both intention-to-treat and per-protocol non-inferiority analyses (11), and is inherent to research in palliative oncology because patients with metastatic disease have short life expectancies. However, it has been argued that intention-to-treat plays an important role in interpretation of non-inferiority trials due to preservation of the integrity of randomization (missing data may not be missing in a randomized manner), as well as providing a representative, real-world estimate of effectiveness (or ineffectiveness) (11). The proportion of patients with missing data was balanced between treatment groups in the SC.20 trial (31% and 33%), which reduced the chance that missing data acted as a source of bias in the analysis (8). Therefore, excluding the considerable proportion of missing patients from final analysis could preclude establishing a realistic picture of benefit or lack thereof. External validity is a major concern in applying any clinical trial result to day-to-day practice, particularly in palliative oncology. An intention-to-treat analysis provides clinicians and patients with data that mirrors reality in the clinic, whereas a per-protocol analysis can obfuscate and confuse.

Let us suppose, for a moment, that 6% is the actual absolute point estimate of improved pain control with multiple-fraction retreatment. The number needed-to-treat (NNT) is 16.7 patients; therefore, 16.7 patients would receive an excess of 67 radiotherapy fractions (16.7×4 fractions) to provide a single patient with improved pain control. To put this into context, use of multiple-fraction retreatment means almost 3 person-months of time that palliative oncology patients need to spend in the radiotherapy clinic. Indeed, this is a conservative estimate given that the intention-to-treat point estimate is 4.0% (NNT =25) and many patients receiving multiple-fractions would receive not five, but eight fractions.

Clinicians should keep in mind that the life expectancy of patients requiring re-irradiation for painful bone metastases is limited. In SC.20, the median survival of patients was between 9.3 to 9.7 months (8); this is likely an overestimate given the inherent bias against enrolling clinical trial participants with comorbidities or advanced age (13). Three other studies have reported survival of patients receiving re-irradiation; these results are summarized in Table 1. Just under 5% of a person’s remaining lifespan could be spent waiting in, and travelling to and from a radiotherapy clinic in a multiple-fraction regimen; this represents a substantial burden upon palliative oncology patients and families that could be reduced with single-fraction re-irradiation. It should be noted, however, that estimation of overall survival was not a primary endpoint of the cited studies and may be subject to bias from patients lost to follow-up.

The SC.20 trial did find statistically significant increases in adverse effects with multiple-fraction treatment, including a 10% absolute increase in dermatitis at 2 weeks, anorexia,
and vomiting (8). Patients also express a preference for single-fraction radiotherapy (in the first-treatment setting) when information is presented in a clear manner to them (18). Finally, numerous cost-effectiveness analyses are available for first-treatment of bone metastases, demonstrating reduced cost to health care systems with single-fraction treatment (19-22).

Effectiveness of single-fraction treatment is described by the randomized SC.20 trial, but also corroborated in a meta-analysis by Bedard et al. (23). In a pooled estimate from a radiotherapy retreatment systematic review (1), the overall response rate was identical between every combination of single-fraction and multiple-fraction treatment and retreatment. For example, overall response rate with single-fraction initial treatment followed by single-fraction or multiple-fraction retreatment was 71% and 72%, respectively; overall response rate with multiple-fraction initial treatment, followed by single-fraction or multiple-fraction retreatment, was identical (73%). Despite these benefits, why do some clinicians continue to offer multiple-fraction retreatment?

A common argument for patients who were initially treated with a single-fraction is that if the initial treatment did not provide pain relief, then retreatment with a single-fraction would be ineffective as well. This is not supported by the evidence (23). Clinician bias to retreatment after initial single-fraction treatment is well documented. In a Radiation Therapy Oncology Group trial (RTOG 9714), patients who received single-fraction treatment had the same pain response as multiple-fractions but ended up receiving more retreatment (24). The Dutch Bone Metastasis Study found single-fraction patients were re-treated sooner, despite having less pain prior to retreatment (25). Other arguments for multiple-fraction treatment include better re-mineralization (26) and potentially reduced fracture rate, but a meta-analysis of first-treatment has not found a statistically significant increase in pathologic fracture or spinal cord compression with single-fraction treatment, even with inclusion of more than 2,000 patients in pooled analysis (1).

There likely exist subsets of patients who may benefit from alternative therapies. Patients with complicated bone metastases or impending pathologic fracture should receive surgery followed by post-operative, fractionated radiotherapy (with attention to cumulative dose-tolerance of organs at risk in retreatment). Cancer patients with painful vertebral compression fractures due to their spine metastasis may benefit from balloon kyphoplasty to provide pain relief (27). Bone metastases arising from radioresistant histologies, such as renal cell carcinoma or melanoma, may benefit from high radiation doses that can be delivered with stereotactic body radiotherapy (SBRT) or fractionated radiation (28). Individuals with oligometastatic disease or expected long survival may also benefit from higher dose with SBRT (5,29) or fractionated radiotherapy to provide local control and pain relief. Thus, fractionated radiotherapy should be considered in post-operative patients, oligometastatic disease, radioresistant histology, or patients with good performance status and expected long survival. Nonetheless, clinicians should be aware of the tendency to over-estimate life expectancy of palliative oncology patients (30), which would then over-estimate the potential benefit of any prolonged fractionation schedule.

In summary, the available data support the feasibility, effectiveness, safety, cost-effectiveness and convenience of single-fraction retreatment. Single-fraction retreatment relieves pain from painful bone metastases, is associated with fewer adverse effects, and minimizes patient and caregiver burden. Although treatment choice and dose-fractionation should always be tailored to the individual patient, single-fraction retreatment should be the default and standard option for most patients with uncomplicated, painful bone metastases.

**Con argument**

Bone metastases are common manifestations in many types of malignancies and may be associated with adverse consequences such as pain, pathological fractures, and

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Median survival (months)</th>
<th>Remaining lifespan used by 4 extra RT days (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SC.20 (8)</td>
<td>850</td>
<td>9.5</td>
<td>1.4</td>
</tr>
<tr>
<td>Jeremic et al. (14)</td>
<td>109</td>
<td>5.5</td>
<td>2.4</td>
</tr>
<tr>
<td>Hayashi et al. (15,16)</td>
<td>30</td>
<td>4</td>
<td>3.3</td>
</tr>
<tr>
<td>Hernanz et al. (17)</td>
<td>22</td>
<td>3</td>
<td>4.4</td>
</tr>
</tbody>
</table>
neurological compromise. Radiotherapy is an effective treatment modality for palliation of painful bony metastases (5,8). With advances in systemic therapy, the average life expectancy of cancer patients has been prolonged (15). Consequently, increased numbers of patients survive to develop recurrent pain after previous radiation treatment (8). Repeat treatment of bony metastases has been shown to be feasible and effective in alleviating pain (17,31,32).

Radiation dose and fractionation are important considerations in the retreatment setting, and normal structure tolerances need to be considered in the context of previous irradiation. A variety of fractionation schedules were identified in a recent systematic review of retreatment (15). Our esteemed colleagues arguing for the pro position purported that a single 8 Gy should be the standard of care in the retreatment of uncomplicated bony metastases. However, we believe that while a single 8 Gy is an option, it has not been shown to be superior to fractionated regimens.

The legal definition of “standard of care” is “the caution that a reasonable person in similar circumstances would exercise in providing care to a patient” (33). There is no clear medical definition for this standard of care; however, it is widely considered to be the “conscientious, explicit, and judicious use of the current best evidence in making decisions about the care of individual patients” and the term should be used only if “supported by confirmatory RCTs or meta-analysis that are unchallenged”. We believe that there is insufficient evidence to support the statement that a single 8 Gy should be the sole standard fractionation for the retreatment of uncomplicated bone metastases.

To our knowledge, the only strong randomized evidence in this regard is NCIC SC.20 (8), a well-designed non-inferiority trial comparing a single 8 Gy fraction to 20 Gy fractionated radiotherapy. Patients with spinal cord compression, pathological fractures, or impending fractures were excluded. The primary endpoint was pain response at two months and secondary endpoints included quality of life and toxicity. The study failed to demonstrate non-inferiority for the primary endpoint on per-protocol analysis and the term should be used only if “supported by confirmatory RCTs or meta-analysis that are unchallenged”. We believe that there is insufficient evidence to support the statement that a single 8 Gy should be the sole standard fractionation for the retreatment of uncomplicated bone metastases.

Another randomized study demonstrated retreatment rates of 2% vs. 28% (P=0.001) in fractionated and single treatment groups, respectively (35). Given that a third course of radiotherapy may not be feasible or desirable, we would extrapolate that fractionated radiotherapy may potentially maximize the duration of pain response and minimize the risk of recurrent pain.

Lastly, while NCIC SC.20 demonstrated no statistically significant difference in the rates of in-field pathological fractures and spinal cord compression/cauda equina syndrome between the two groups, there is evidence that fractionated treatment may be advantageous in increasing
remineralization. A randomized trial demonstrated significantly more bone recalcification in patients with fractionated treatment, compared to single-fraction (26). The authors concluded that fractionated treatment leads to “better stabilization”, which theoretically may lead to decreased rates of subsequent fractures. Similarly, in the Dutch Bone Metastasis Study, more pathological fractures were observed in the single-fraction group (19).

Overall, there does not seem to be consistent evidence regarding response rates, durability, and toxicity which would support holding one dose-fractionation scheme over another in the setting of retreatment of uncomplicated bone metastases. Though NCIC SC.20 suggested that 8 Gy in a single-fraction was non-inferior to a fractionated 20 Gy schedule, there are scenarios in which fractionation may be preferable. Therefore, both patient and tumour factors need to be considered when determining dose and fractionation in the retreatment setting. For example, fractionated treatment may be preferred in patients who have a longer life expectancy as it may result in a longer duration of response. Similarly, fractionated treatment may increase bone stabilization in weight-bearing regions and minimize the risk of pathological fractures. A patient who was treated with single-fraction radiotherapy as first-treatment, now needing retreatment, may prefer a different dose-fractionation, electing to receive multiple-fraction retreatment. Furthermore, in cases where local control is important (radioresistant tumours or oligometastatic disease), single-fraction 8 Gy treatment may be inappropriate. Thus, there are a variety of situations where single-fraction retreatment is not preferred: patient preference, long anticipated survival, oligometastatic

### Table 2 Pooled response rates by retreatment dose and fractionation (15)

<table>
<thead>
<tr>
<th>Fractionation</th>
<th>Total patients</th>
<th>Response rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 Gy/1</td>
<td>167</td>
<td>73.7</td>
</tr>
<tr>
<td>6 Gy/1</td>
<td>19</td>
<td>68.4</td>
</tr>
<tr>
<td>8 Gy/1</td>
<td>114</td>
<td>64.9</td>
</tr>
<tr>
<td>10 Gy/1</td>
<td>3</td>
<td>100</td>
</tr>
<tr>
<td>All single-fraction</td>
<td>309</td>
<td>70</td>
</tr>
<tr>
<td>20 Gy/5</td>
<td>4</td>
<td>100</td>
</tr>
<tr>
<td>24 Gy/6</td>
<td>85</td>
<td>62.4</td>
</tr>
<tr>
<td>30 Gy/10</td>
<td>14</td>
<td>100</td>
</tr>
<tr>
<td>All multiple fractions</td>
<td>166</td>
<td>75</td>
</tr>
</tbody>
</table>

Disease, critical weight-bearing bone, or radioresistant histology. Therefore, a single-fraction of 8 Gy should not be considered the sole standard of care.

**Discussion**

Strauss and Thomas (33) indicated that there is no medical definition of standard of care. However, it was recommended that the term “standard of care” be used when there is support from confirmatory RCTs or meta-analysis that are unchallenged. Therefore, the term standard of care should be used with caution. The authors note, that the use of standard of care can be abused with the intention of providing impact and authenticity to a point of view that may be self-rewarding, without support from strong evidence.

Although the NCIC SC.20 trial concluded that, “In patients with painful bone metastases requiring repeat radiation therapy, treatment with 8 Gy in a single-fraction seems to be non-inferior and less toxic than 20 Gy in multiple fractions”, it should be noted that “the findings were not robust in a per-protocol analysis”. When choosing between single or multiple retreatment regimens, the authors concluded that trade-offs between efficacy and toxicity might exist. As such, single-fraction repeat radiation for painful bone metastases is an option as is multiple fractions. Both single and multiple fractions for re-irradiation of uncomplicated painful bone metastases are supported from this RCT.

In the absence of strong, randomized evidence demonstrating superiority of one treatment over another, other factors may be used by clinicians to decide between single and multiple fraction retreatments. However, reimbursement patterns should not be a factor in determining a dose-fractionation regimen of choice, even though remuneration is hypothesized to be a factor that influences variation in fractionation choice between countries (2). Instead, decisions regarding which fractionation regimen to use should depend on patient, tumour and treatment factors. In a patient with good performance status, quiescent systemic disease and in a patient who would not find it too burdensome to return for fractionated radiotherapy, multiple fractions for retreatment may be favoured with the possibility of more durable pain relief. However, these patients could also be re-treated with a single 8 Gy, which was found not to be inferior in the SC.20 trial.

On the other hand, if a patient has poor performance
status and returning for multiple fractions would be a significant burden to the patient, single-fraction repeat radiotherapy would be favored. So, with respect to the debate statement: single-fraction treatment should be standard in the retreatment of uncomplicated bone metastases. The answer is yes, it is a standard of care. But multiple fractions are also a standard of care for these patients. The choice among the different fractionation schemes depends on an assessment of individual patient factors, tumour factors and unique patient circumstances.

Conclusions

Randomized trials have demonstrated feasibility, effectiveness, cost-effectiveness and convenience of single-fraction retreatment of painful bone metastases. At the same time, questions exist regarding non-inferiority of pain response and durability of pain relief with single-fraction retreatment. Without definitive data supporting one fractionation scheme over another, both 8 Gy in a single fraction or 20 Gy in multiple fractions are valid, standard options for patients. Choice of a dose-fractionation regimen should be made in discussion with the patient, their family, as well as oncologists and palliative care physicians in the circle of care. Factors important in this discussion include the patient’s performance status, projected life expectancy, social situation, and treatment philosophy.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References
